UCSF PANC Cyst Registry

Pancreatic Cancer Clinical Trial

— UCSF PCR  

Official title:

Population-Based Analysis of Neoplastic Changes in Cystic Lesions of the Pancreas.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04291651
• Other study ID #: 214521
• Status: Recruiting
• Start date: October 8, 2019
• Est. completion date: January 1, 2030

Study information

• Verified date: July 2023
• Source: University of California, San Francisco
• Contact: Charysa Santos, BS
• Phone: 415-514-6914
• Email: Charysa.Santos[@]ucsf.edu
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provides an opportunity to diagnose pancreatic malignancy at an early, curable stage yet also increases the potential to over-treat clinically insignificant lesions. This presents a clinical challenge to prevent unnecessary resection of indolent disease, with associated risks of infections, bleeding, diabetes, and costly disability. Unfortunately, there is little information on the epidemiology and natural history of pancreatic cysts to help guide management.

Description:

This study develops a large, prospectively managed, electronic, patient-directed pancreatic cyst registry based at UCSF. The UCSF Pancreatic Cystic Lesions Registry (PANC Cyst) will facilitate work to improve clinical care and understanding of pancreatic cysts by prospective follow-up of patients with cystic lesions, especially the diagnostically challenging small cysts, to identify factors related to cyst formation and progression to malignancy. Longitudinal data capture that includes clinical outcomes will also enable us to more precisely define anatomic, radiographic and biomarker information that can be used to differentiate populations of patients for whom surgery is indicated, surveillance is warranted, or no further evaluation is necessary.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 4000
• Est. completion date: January 1, 2030
• Est. primary completion date: January 1, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The inclusion criteria for this study are intentionally broad. Eligible patients for prospective enrollment will include

• Adults = 30 years of age

• Have a radiographic or endoscopic diagnosis of at least one pancreatic cysts regardless of treatment status,

• No history of pancreatic cancer,

• Can speak and read English,

• Have access to a computer or mobile device (~95% of U.S. population); and

• Are able to complete an electronic informed consent.

Exclusion Criteria:

• Patients who don't speak English,

• Don't have access to a computer or mobile device; or

• Patients who have a cancer diagnosis.

Related Conditions & MeSH terms

• Cysts
• Intraductal Papillary Mucinous Neoplasm
• Mucinous Cyst
• Neoplasms
• Neoplasms, Cystic, Mucinous, and Serous
• Pancreatic Cancer
• Pancreatic Cyst
• Pancreatic Diseases
• Pancreatic Ductal Adenocarcinoma
• Pancreatic Neoplasms

Intervention

Other:
• Survey
There are no study-specific interventions, as this is a prospective registry. However, patients will be asked to complete approximately 1-2 hours worth of surveys on things such as demographics, medical and surgical history, and pancreatic cyst-specific questionnaires.

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cancer	While not the primary outcome measure, the development of cancer from a pancreatic cyst is a critically important study endpoint, which the investigators do not expect to be frequent occurrence.	1-10 years
Primary	Indolency	If a patient with a pancreatic cyst experiences no or minimal change in size, and no development of worrisome or high-risk stigmata (Tanaka 2017), this will be considered to be an indolent lesion. Most patients will fall under this category.	1-10 years